Navigation Links
Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
Date:12/22/2011

SAN DIEGO, Dec. 22, 2011 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the completion of its public offering of 5,646,173 units.  Each unit consisted of one share of common stock and a warrant to purchase ten shares of common stock, at a price to the public of $1.45 per share of common stock and $1.449 per warrant to purchase each share of common stock, which together comprised the purchase price of $15.94 per unit.   Net proceeds, after underwriting discounts and commissions and estimated expenses, were approximately $86.9 million.  The underwriter does not have an option to purchase any additional units in this offering. Leerink Swann LLC acted as sole manager for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 17, 2009.  The offering was made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained from Leerink Swann LLC , Attention: Syndicate Department, One Federal Street, 37th Fl., Boston, MA 02110 or by calling Leerink Swann LLC, toll free, at 1-800-808-7525, Ext. 4814.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Orexigen® Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Contrave® has completed Phase 3 clinical trials, and the Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.

 

 

 


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen® Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
2. Orexigen® Therapeutics Presents Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
3. Orexigen® Therapeutics Reports Second Quarter Ended June 30, 2011 Financial Results
4. Orexigen® Therapeutics Provides a Regulatory Update on Contrave® NDA
5. Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
6. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
7. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
8. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
11. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017 AMRI , a ... been working with the life sciences industry to improve ... 25 years, has been recognized for its excellence as ... as part of the Life Science Leader,s 2017 ... expertise, quality and reliability. "Competing with ...
(Date:3/22/2017)... STOCKHOLM , March 22, 2017 ... biopharmaceutical company developing novel anticancer therapies targeting the ... with Memorial Sloan Kettering Cancer Center to study ... p53 by APR-246. The goal of ... efficacy of APR-246 in combination with multiple other ...
(Date:3/22/2017)... Research and Markets has announced the addition of the "Global ... ... market to grow at a CAGR of 14.58% during the period ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... ... leading digital and print media enterprise focused on cancer patients, cancer centers and ... released a special 12-part educational video series, “No Ifs, Ands, or Butts,” that ...
(Date:3/22/2017)... ... 22, 2017 , ... The Rett Syndrome Research Trust (RSRT) ... that afflicts 350,000 individuals worldwide. Rett Syndrome is caused by alterations in ... females. Following a normal infancy, Rett Syndrome takes effect in toddlerhood depriving ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... to its Department of Orthopedic Surgery, Division of Hand, Upper Extremity and Microvascular ... surgery. She is board-certified in both Orthopedics and Hand Surgery. , ...
(Date:3/22/2017)... ... March 22, 2017 , ... Intrinsic Imaging, ... therapeutic experience and operational excellence in oncology clinical trials, proudly announces today that ... treatment of non-small cell lung cancer and small cell lung cancer. , Throughout ...
(Date:3/22/2017)... Norwich, NY (PRWEB) , ... March 22, 2017 , ... ... to communities in the greater Nassau County region, is embarking on a combined charity ... breast cancer. , For the last 25 years, the Great Neck Breast Cancer ...
Breaking Medicine News(10 mins):